NICE is unable to make a recommendation about the use in the NHS of crisaborole for treating mild to moderate atopic dermatitis in people 2 years and older. This is because Pfizer withdrew its evidence submission. The company has confirmed that it does not wish to make an evidence submission for the appraisal because currently the technology will not be launched in the UK.


If NHS organisations wish to consider crisaborole for this indication, they should follow the advice on rational local decision making in the NHS Constitution for England and the NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012. This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-4144-5

  • National Institute for Health and Care Excellence (NICE)